#H1N1 FLU NEWS SCAN: Sanofi's quadrivalent vaccine, digital archive on 1918 ... - CIDRAP http://t.co/WWyX1cz6
Sanofi Pasteur announced today that it has applied for licensure of a quadrivalent (four-strain) version of its Fluzone flu vaccine, containing two influenza B strains, and expects a decision from the Food and Drug Administration (FDA) in the second quarter of 2013. The move is a response to the difficulty of predicting which of two type B lineages—Victoria or Yamagata—will be more common each season. "It makes sense to include both in the vaccine rather than attempting to predict which of the two will be the dominant strain," said David Greenberg, MD, Sanofi's senior director of US scientific and medical affairs, in a press release. He added that in 6 of the past 12 seasons, the B strain picked for the vaccine was not the predominant one during the ensuing season. The release noted that seasonal flu vaccines contained just two strains, one A and one B, until 1978, when authorities decided to recommend a second type A strain in view of the co-circulation of two subtypes (H3N2 and H1N1). The Sanofi move comes about 7 months after the FDA approved a quadrivalent intranasal vaccine made by MedImmune Inc., which is expected to be marketed in time for the 2013-14 flu season. Sanofi said its Fluzone quadrivalent vaccine is intended for everyone older than 6 months. The company is also working on quadrivalent versions of its other US flu vaccines, Fluzone High-Dose (for seniors) and FluZone Intradermal.
Link -
Trackbacks